CVS Health Launches Workforce Innovation and Talent Center in Chicago to Strengthen Community Employment and Training Opportunities In a significant step toward fostering economic opportunity and addressing workforce gaps, CVS Health has officially launched its newest Workforce Innovation and Talent…
FDA Approves Streamlined Monitoring Requirements and REMS Program Removal for Bristol Myers Squibb’s CAR T Cell Therapies Breyanzi and Abecma, Marking Milestone Toward Expanding Access to Cancer Treatment In a significant regulatory development, Bristol Myers Squibb announced that the U.S.…
Merck’s ENFLONSIA Receives ACIP Endorsement for RSV Prevention in Infants, Marking a Major Milestone in Pediatric Infectious Disease Prevention U.S. CDC panel backs long-acting monoclonal antibody to protect infants during their first RSV season; drug also included in federal Vaccines…
Global Energy Access Expands, But Urgent Financing Needed to Bridge Persistent Gaps and Achieve SDG 7 by 2030 A newly released edition of the Tracking SDG 7: The Energy Progress Report 2025 reveals that the world has made substantial strides…
Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating salanersen (BIIB115/ION306), an investigational antisense oligonucleotide (ASO) therapy for spinal…
Bharat Biotech and GSK Commit to Affordable Access to RTS,S, the World’s First Malaria Vaccine, with Major Price Reduction and Expanded Availability in Africa Bharat Biotech International Limited (BBIL) and GSK plc have jointly announced a pivotal step toward global…
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc., a biotechnology firm known for its expertise in microRNA-targeting…
FDA Approves Label Update for Lilly’s Amyvid, Expanding Its Role in Alzheimer’s Disease Diagnosis and Therapy Guidance In a major development for Alzheimer’s diagnostics, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has…
Revolution Medicines Secures $2 Billion Strategic Funding from Royalty Pharma to Accelerate Development and Global Commercialization of RAS(ON) Inhibitor Portfolio Revolution Medicines, a leading late-stage oncology company focused on precision therapies for genetically defined cancers, has announced a landmark funding…
Bio-Techne and USP Forge Strategic Alliance to Advance Quality Standards in Monoclonal Antibody and Gene Therapy Development Bio-Techne Corporation, a global life sciences company renowned for its high-performance reagents, instruments, and services, today announced a new distribution agreement with the…
Royalty Pharma and Revolution Medicines Forge $2 Billion Strategic Funding Pact to Accelerate Global Development of RAS Cancer Therapies Royalty Pharma plc, a prominent funder of innovation in the biopharmaceutical industry, announced a transformative agreement with Revolution Medicines, Inc., securing…
Baxter Releases 2024 Corporate Responsibility Report, Underscoring Sustainability, Stakeholder Engagement, and Global Impact Baxter International,a global leader in medical technology, has published its 2024 Corporate Responsibility Report, reaffirming the company’s dedication to creating a positive social, environmental, and economic impact…